Mallinckrodt Plc and Cancer Prevention Pharmaceuticals Inc Announce Results from Pivotal Phase 3 Trial of CPP-1X/Sulindac in Pat
Conference Call Mallinckrodt Plc
Mallinckrodt Plc Conference call or earnings call will be held on May 19, 2019 via an 800 number (toll-free). During the earnings conference call's session Mallinckrodt Plc will provide updated information and financial status.
Conference call is also referred to as: teleconference call or audio conference bridge. Conferencing service is provided in house or as cloud based teleconference service.
In order to join the audio conferencing dial conference bridge and key in the PIN code, Contact Mallinckrodt Plc for this information
Schedule a teleconference with QCONF and get 5 free calls with our conference service.
Mallinckrodt plc and its subsidiaries (collectively, "Mallinckrodt" or "the Company"), is a global specialty biopharmaceutical and nuclear imaging business that develops, manufactures, markets and distributes specialty pharmaceutical and biopharmaceutical products and nuclear imaging agents. Therapeutic areas of focus include autoimmune and rare disease specialty areas (including neurology, rheumatology, nephrology and pulmonology); immunotherapy and neonatal respiratory critical care therapies; pain management; and central nervous system drugs. The Company also supports the diagnosis of disease with nuclear medicine imaging agents. The Company believes its experience in the acquisition and management of highly regulated raw materials; deep regulatory expertise; and specialized chemistry, formulation and manufacturing capabilities have created compelling competitive advantages that it anticipates will sustain future revenue growth.Read more Conference Call